Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders

Blood Cells, Molecules, and Diseases

Volumn 54, Issue 3, 2015, Pages 286-291

  Chotirat, Sadudee ^a   Thongnoppakhun, Wanna ^a   Wanachiwanawin, Wanchai ^a   Auewarakul, Chirayu U ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Aplastic anemia; IDH mutations; Myelodysplastic syndrome; Myeloproliferative neoplasms; Paroxysmal nocturnal hemoglobinuria; Preleukemia disorders

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; APLASTIC ANEMIA; ARTICLE; CHROMOSOME 15; CHROMOSOME 2; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HETEROZYGOSITY; HUMAN; IDH1 GENE; IDH2 GENE; INCIDENCE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRELEUKEMIA; PREVALENCE; PRIORITY JOURNAL; SOMATIC MUTATION; VERY ELDERLY; ACUTE MYELOBLASTIC LEUKEMIA; COHORT ANALYSIS; GENETIC POLYMORPHISM; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; BASE SEQUENCE; COHORT STUDIES; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84923838335     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.11.017     Document Type: Article

References (43)

1. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368(9550):1894-1907.
2. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 1999, 341(14):1051-1062.
3. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(7):2548-2553.
4. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010, 70(2):447-452.
5. Harris J.W., Koscick R., Lazarus H.M., Eshleman J.R., Medof M.E. Leukemia arising out of paroxysmal nocturnal hemoglobinuria. Leuk. Lymphoma 1999, 32(5-6):401-426.
6. Lin C.C., Hou H.A., Chou W.C., Kuo Y.Y., Liu C.Y., Chen C.Y., et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am. J. Hematol. 2014, 89(2):137-144.
7. Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24(7):1302-1309.
8. Nowell P.C. Preleukemia. Cytogenetic clues in some confusing disorders. Am. J. Pathol. 1977, 89(2):459-476.
9. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 2010, 16(9):387-397.
10. Corpas F.J., Barroso J.B., Sandalio L.M., Palma J.M., Lupianez J.A., del Rio L.A. Peroxisomal NADP-dependent isocitrate dehydrogenase. Characterization and activity regulation during natural senescence. Plant Physiol. 1999, 121(3):921-928.
11. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462(7274):739-744.
12. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324(5924):261-265.
13. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17(3):225-234.
14. Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 2009, 30(1):7-11.
15. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812.
16. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360(8):765-773.
17. Chou W.C., Hou H.A., Chen C.Y., Tang J.L., Yao M., Tsay W., et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010, 115(14):2749-2754.
18. Abbas S., Lugthart S., Kavelaars F.G., Schelen A., Koenders J.E., Zeilemaker A., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010, 116(12):2122-2126.
19. Boissel N., Nibourel O., Renneville A., Gardin C., Reman O., Contentin N., et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J. Clin. Oncol. 2010, 28(23):3717-3723.
20. Chotirat S., Thongnoppakhun W., Promsuwicha O., Boonthimat C., Auewarakul C.U. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J. Hematol. Oncol. 2012, 5:5.
21. Wagner K., Damm F., Gohring G., Gorlich K., Heuser M., Schafer I., et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J. Clin. Oncol. 2010, 28(14):2356-2364.
22. Kosmider O., Gelsi-Boyer V., Slama L., Dreyfus F., Beyne-Rauzy O., Quesnel B., et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010, 24(5):1094-1096.
23. Thol F., Weissinger E.M., Krauter J., Wagner K., Damm F., Wichmann M., et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010, 95(10):1668-1674.
24. Pardanani A., Patnaik M.M., Lasho T.L., Mai M., Knudson R.A., Finke C., et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010, 24(7):1370-1372.
25. Pardanani A., Lasho T.L., Finke C.M., Mai M., McClure R.F., Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010, 24(6):1146-1151.
26. Green A., Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N. Engl. J. Med. 2010, 362(4):369-370.
27. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361(11):1058-1066.
28. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 2010, 28(22):3636-3643.
29. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60years and unmutated NPM1 status. Blood 2010, 116(25):5486-5496.
30. Chao H.Y., Jia Z.X., Chen T., Lu X.Z., Cen L., Xiao R., et al. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype. Int. J. Lab. Hematol. 2012, 34(5):502-509.
31. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364(26):2496-2506.
32. Jin J., Hu C., Yu M., Chen F., Ye L., Yin X., et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One 2014, 9(6):e100206.
33. Lin J., Yao D.M., Qian J., Chen Q., Qian W., Li Y., et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann. Hematol. 2012, 91(4):519-525.
34. Lin T.L., Nagata Y., Kao H.W., Sanada M., Okuno Y., Huang C.F., et al. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica 2014, 99(1):28-36.
35. Patnaik M.M., Hanson C.A., Hodnefield J.M., Lasho T.L., Finke C.M., Knudson R.A., et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012, 26(1):101-105.
36. Patnaik M.M., Lasho T.L., Finke C.M., Gangat N., Caramazza D., Holtan S.G., et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010, 24(7):1283-1289.
37. Tefferi A., Jimma T., Sulai N.H., Lasho T.L., Finke C.M., Knudson R.A., et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012, 26(3):475-480.
38. Kannim S., Auewarakul C.U. The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders. Int. J. Cancer 2009, 125(4):988-990.
39. Hussein K., Engelhardt B.M., Kreipe H., Bock O. IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasms. Blood 2010, 116(23):5073-5074.
40. Zou Y., Zeng Y., Zhang D.F., Zou S.H., Cheng Y.F., Yao Y.G. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem. Biophys. Res. Commun. 2010, 402(2):378-383.
41. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18(6):553-567.
42. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19(1):17-30.
43. DiNardo C.D., Propert K.J., Loren A.W., Paietta E., Sun Z., Levine R.L., et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013, 121(24):4917-4924.